Please assess the completion status of the following clinical trial:

Trial Title: Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented evidence of multiple myeloma (per local assessment):~* Monoclonal plasma cells in the bone marrow greater than or equal to 10% and/or presence of a biopsy-proven plasmacytoma, and~* Monoclonal protein present in the serum and/or urine~* Radiographic (X-ray, or computer tomography \[CT\]) evidence of at least 1 lytic bone lesion (or at least 1 focal lesion per magnetic resonance imaging \[MRI\])~* Plan to receive or is receiving primary frontline anti-myeloma therapies~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2~* Age ≥ 18 years~* Adequate organ function, as defined by the following criteria (per central or local laboratory values):~  * Serum aspartate aminotransferase (AST) ≤ 2.0 x upper limit of normal (ULN)~ * Serum alanine aminotransferase ≤ (ALT) 2.0 x ULN~ * Serum total bilirubin ≤ 2.0 x ULN~ * Creatinine clearance ≥ 30 mL/min~ * Serum calcium or albumin-adjusted serum calcium 2.0 mmol/L (8.0 mg/dL) and 2.9 mmol/L (11.5 mg/dL)~* Written informed consent before any study-specific procedure is performed~Exclusion Criteria:~* Nonsecretory multiple myeloma based upon standard M-component criteria (ie, measurable serum/urine M-component) unless the baseline serum free light chain level is elevated~* POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)~* Plasma cell leukemia~* More than 30 days of previous treatment (before screening) with anti-myeloma therapy (does not include radiotherapy or a single short course of steroid \[ie, less than or equal to the equivalent of dexamethasone 60 mg/day for 4 days\]).~* Planned radiation therapy or surgery to the bone (does not include procedures performed before randomization)~* Prior administration of denosumab~* Use of oral bisphosphonates with a cumulative exposure of more than 1 year~* More than 1 previous dose of IV bisphosphonate administration~* Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw~* Active dental or jaw condition which requires oral surgery, including tooth extraction~* Non-healed dental/oral surgery, including tooth extraction~* Planned invasive dental procedures~* Evidence of any of the following conditions per subject self-report or medical chart review:~  * Any prior invasive malignancy within 5 years before randomization~ * Any non-invasive malignancy not treated with curative intent or with knownactive disease within 5 years before randomization~ * Major surgery or significant traumatic injury occurring within 4 weeks before randomization~ * Active infection with Hepatitis B virus or Hepatitis C virus~ * Known infection with human immunodeficiency virus (HIV)~ * Active infection requiring IV anti-infective therapy~* Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after end of treatment~* Female subject of child bearing potential is not willing to use highly effective contraception during treatment and for 5 months after the end of treatment (see section 6.3)~* Known sensitivity to any of the products to be administered during the study (eg, mammalian derived products, calcium or vitamin D)~* Subject is receiving or is less than 30 days since ending other experimental device or drug (no marketing authorization for any indication)~* Subject will not be available for follow-up assessment~* Any major medical or psychiatric disorder that in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zoledronic acid (Type: ACTIVE_COMPARATOR): Zoledronic acid 4 mg intravenously plus placebo to denosumab subcutaniously (SC) once every 4 weeks (Q4W) in the double-blind treatment period (Since denosumab was determined to have a positive benefit:risk profile in the primary analysis of the study, per protocol, participants who were still undergoing Q4W scheduled assessments were offered open-label denosumab 120 mg SC Q4W for up to 2 years)
- Denosumab (Type: EXPERIMENTAL): Denosumab 120 mg subcutaniously (SC) plus placebo to zoledronic acid intravenously once every 4 weeks (Q4W) in the double-blind treatment period (Since denosumab was determined to have a positive benefit:risk profile in the primary analysis of the study, per protocol, participants who were still undergoing Q4W scheduled assessments were offered open-label denosumab 120 mg SC Q4W for up to 2 years)

Based on this trial design, predict the completion outcome and termination type (if applicable).